What is HC Wainwright’s Forecast for TSE:ONC Q2 Earnings?

Oncolytics Biotech Inc. (TSE:ONC) – Stock analysts at HC Wainwright reduced their Q2 2026 EPS estimates for Oncolytics Biotech in a research report issued on Tuesday, May 26th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.10) for the quarter, down from their previous forecast of ($0.04). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q3 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.39) EPS, Q1 2027 earnings at ($0.06) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.04) EPS, Q4 2027 earnings at ($0.04) EPS, FY2027 earnings at ($0.21) EPS, FY2028 earnings at ($0.19) EPS and FY2029 earnings at ($0.17) EPS.

Oncolytics Biotech Trading Down 1.3%

Shares of TSE:ONC opened at C$14.90 on Thursday. The stock has a market capitalization of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80. Oncolytics Biotech has a 1-year low of C$0.44 and a 1-year high of C$2.08. The company has a debt-to-equity ratio of 14.58, a quick ratio of 8.86 and a current ratio of 2.88. The company has a 50 day moving average price of C$14.90 and a 200 day moving average price of C$14.90.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.